Cardiomagnil, 150 mg+30.39 mg 30 pcs

Antiplatelet.

Acetylsalicylic acid irreversibly inhibits the enzyme cyclooxygenase and selectively reduces the synthesis of thromboxane A2, which leads to reduced platelet aggregation and decreased blood clotting.

Magnesium hydroxide protects the mucous membranes of the gastrointestinal tract, which reduces the risk of side effects.

Indications

Active ingredient

Composition

White film-coated tablets, oval shape, with a rib on one side.

Acetylsalicylic acid 150 mg in 1 tablet. Magnesium hydroxide 30.39 mg in 1 tablet.

Associates

How to take, the dosage

The tablet should be swallowed whole with water. If desired, the tablet may be broken in half, chewed, or pre-mashed.

Primary prevention of cardiovascular disease For primary prevention of cardiovascular disease such as thrombosis and acute heart failure in the presence of risk factors (e.g., diabetes, hyperlipidemia, arterial hypertension, obesity, smoking, advanced age), 1 tablet is indicated. Cardiomagnil, containing acetylsalicylic acid at a dose of 150 mg for the first day, then 1 tablet is prescribed. Cardiomagnacil containing acetylsalicylic acid in a dose of 75 mg once daily.

Prevention of recurrent myocardial infarction and blood vessel thrombosis To prevent recurrent myocardial infarction and blood vessel thrombosis, 1 tablet is prescribed. Cardiomagnacil containing acetylsalicylic acid at a dose of 75-150 mg once daily.

Prevention of thromboembolism after vascular surgery To prevent thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty), 1 tablet is prescribed. Cardiomagnanil containing acetylsalicylic acid at a dose of 75-150 mg once daily.

In case of unstable angina pectoris, 1 tablet of Cardiomagnacil containing acetylacetic acid is prescribed. Cardiomagnil containing acetylsalicylic acid in a dose of 75-150 mg once daily.

Interaction

When using Cardiomagnanil in high doses simultaneously with oral anticoagulants, the effect of the latter may be enhanced.

In coadministration, Cardiomagnesin (in high doses) weakens the uricosuric effect of probenecid.

When used concomitantly, Cardiomagnol increases the effect of chlorpropamide, antiaggregants, fibrinolytic agents and weakens the effect of spironolactone.

In concomitant use, antacids and colestyramine decrease absorption of acetylsalicylic acid.

Special Instructions

The drug is prescribed with caution in patients with a history of peptic ulcer disease.

The patient should be warned to consult a physician if any adverse events occur.

Contraindications

Pregnancy and lactation The drug is contraindicated in the I and III trimesters of pregnancy and during lactation (breastfeeding).

Overdose

In adults, a dose of the drug corresponding to 150 mg of acetylsalicylic acid per 1 kg of body weight is dangerous.

Symptoms: tinnitus, decreased hearing acuity, dizziness, increased sweating, restlessness, abdominal pain, nausea, vomiting (possibly with blood), rapid breathing, increased bleeding time; rarely – heart failure; in single cases – pulmonary edema.

Treatment: if necessary, symptomatic therapy is carried out.

Similarities